Simcere Steps Up Efforts In Antitumor Sector

Simcere Pharmaceutical Group has launched its antitumor drug Jiebaishu (Nedaplatin for injection) on a high note in Beijing, Shanghai and Guangzhou. The drug became a brand under the company since it acquired 85.7 percent stake in Nanjing Dongjie Pharmaceutical late last year. Added to its Endostar purchase in 2006, the company has developed into a sizable force in the antitumor sector. According to Simcere, Jiebaishu currently accounts for over 80 percent of Nedaplatin's domestic market share. Simcere's strategy focuses on the business of innovative drugs or branded but off-patent drugs by first launching in China. Antitumor drugs are ideal for such a model and the company believes product-oriented acquisition is key to reaching its target market. (Click here for more - Chinese Language)